The temperature is rising in the Warner Bros Discovery chase, with key figures at Netflix and Paramount ridiculing the other ...

In January 2026, BlackBerry reported its third consecutive quarter of GAAP profitability, with QNX revenue growth held back by project deferrals and platform launch delays, while media coverage ...

The two U.S. markets regulators will have a joint event to highlight their unified crypto agenda, following the arrival of ...

Business leaders, as a result, are becoming anxious about the blowback — even as they rhapsodize about the coming AI ...

IRS Direct File, which was offered in 25 states last year, has been discontinued. But one very-much underused, free program ...

Shares of BitGo (BTGO), which went live on the New York Stock Exchange (NYSE) on Thursday, are down 12% midday on Friday, ...

If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone.

JetBlue Airways (JBLU) is back in focus after Jim Cramer criticized its recent earnings and outlook, following a single ...

Sangamo Therapeutics is back in focus as the latest price target reset gives investors fresh clues about how the story around this gene therapy name is evolving. With the prior target now withdrawn ...

Key Insights Significant control over FinWise Bancorp by individual investors implies that the general public has ...

After President Trump scrapped planned tariffs on European allies, easing worries about a transatlantic trade clash, ...

Why RAPT Therapeutics is Back on Investors’ Radar RAPT Therapeutics (RAPT) has drawn attention after a sharp move in its share price, with the stock showing strong gains over the past year and ...